According to the latest report by IMARC Group, titled “Ischemic Heart Disease (IHD) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, the global Ischemic Heart Disease drugs market share is expected to exhibit strong growth during 2021-2026. Looking forward, IMARC Group expects the global ischemic heart disease (IHD) drugs market to grow at a CAGR of around 10% during 2021-2026. Ischemic heart disease, also known as coronary heart (CHD) or coronary artery disease, refers to a heart problem in which the blood flow to the heart is restricted or reduced. This is caused by clogged arteries that supply less blood and oxygen to the heart muscles, eventually leading to a cardiac attack. The diverse pharmacological actions of various IHD drugs, such as calcium channel blockers, inhibit the influx of calcium ions into the myocardium and vascular smooth muscle tissues. The relaxation of the coronary artery due to calcium channel blocker therapy improves coronary blood flow, thereby increasing myocardial oxygen supply. The anti-ischemic effects of these drugs are often notable, especially the newer agents like amlodipine.
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviors of the consumers globally–our estimates about the latest market trends and forecast values after considering the impact of this pandemic. These observations will be integrated into the report.
Request for a free sample copy of this report: https://www.imarcgroup.com/ischemic-heart-disease-market/requestsample
Global IHD Drugs Market Trends:
In recent years, the increasing prevalence of heart diseases, along with the growing population of older adults who are more prone to heart ailments, has led to the rising demand for IHD drugs. Moreover, IHD drugs are incorporated in various cardiological treatment procedures, such as angioplasty, atherectomy and balloon angioplasty, for preventing relapse and ensuring healthy recovery, which has led to a consistent requirement for these drugs. Besides this, the high alcohol consumption, excessive smoking, reduced blood pressure control and lower physical activity are the factors that have increased the mortality rate from cardiovascular disease, which in turn is leading to a rise in the demand for IHD drugs across the globe.
Explore Full Report with TOC & List of Figure: https://bit.ly/3nXc5GN
Key Market Segmentation:
Competitive Landscape with Key Players:
- Bayer AG
- Eli Lilly and Company
- Novartis International AG
- Pfizer, Inc.
- Sanofi S.A.
- Actelion Pharmaceuticals Ltd.
- Baxter International Inc.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Amgen Inc.
- Hoffmann-La Roche AG
- GlaxoSmithKline Plc
- Merck & Co.
- Eisai Co., Ltd.
Market Breakup by Disease Class:
- Angina Pectoris
- Myocardial Infarction
Market Breakup by Drug Class:
- Anti-Dyslipidemic Drugs
- Calcium Channel Blockers
- ACE Inhibitors
- Antithrombotic Agents
Market Breakup by Region:
- North America
- Asia Pacific
- Middle East and Africa
- Latin America
Key Highlights of the Report:
- Market Performance (2015-2020)
- Market Outlook (2021- 2026)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
Browse More Research Reports:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800